Four scientists have shared the 2022 Kavli Prize in neuroscience, "for pioneering the discovery of genes underlying a range of serious brain disorders," together and separately.

By analyzing single-cell responses to ketamine administration, a multinational team of researchers has identified a potassium channel that contributes to the long duration of ketamine administration.

In two separate studies, researchers have identified how peripheral nerve injury can lead to increased pain sensitivity. The studies were published on May 25, 2022, in Nature and May 26, 2022, in Science, respectively. The mechanisms they identify could lead to new therapeutic approaches to chronic pain and/or pain hypersensitivity.

Age is the biggest risk factor for just about every common disease in high-income countries, which suggests that slowing down cellular aging would have massive effects on individual and public health. Delaying the average onset of Alzheimer’s disease by five years, for example, would roughly halve its prevalence. But in practice, there are no approved anti-aging medications.

“People often think about the genome as the blueprint of the organism, but that’s not really correct,” Steven Quake told reporters at a Science press briefing earlier this week. “The genome is more of a parts list, because every cell type uses different parts.” Quake is president of the Chan Zuckerberg Biohub Network, and professor of bioengineering and applied physics at Stanford University.

More than 10% of Americans suffer from chronic pain, and how to prevent acute pain from turning chronic has been a critical question in pain research. But according to a study published in the May 11, 2022, issue of Science Translational Medicine, that approach has it backwards. In several animal models of pain, the resolution of acute pain was an active process. Chronic pain happened when those active processes failed to occur.

There are 40 years of history behind the development of phosphoinositide 3-kinase (PI3K) inhibitors, Rebecca Dent told her audience at ESMO Breast Cancer 2022. And there have been success stories. There are five FDA-approved PI3K inhibitors in several cancer types, and in April, the FDA approved Vijoice (alpelisib; Novartis AG) for PIK3CA-related overgrowth spectrum, a rare disorder resulting from germline mutations of PIK3CA.

A comparison of seven nonhuman primate species has found both similarities and differences among the effects of age on female reproduction.

There are 40 years of history behind the development of phosphoinositide 3-kinase (PI3K) inhibitors, Rebecca Dent told her audience at ESMO Breast Cancer 2022. And there have been success stories. There are five FDA-approved PI3K inhibitors in several cancer types, and in April, the FDA approved Vijoice (alpelisib; Novartis AG) for PIK3CA-related overgrowth spectrum, a rare disorder resulting from germline mutations of PIK3CA.